Do device characteristics impact outcome in carotid artery stenting?  by Hart, Joseph P. et al.
From the Society for Vascular Surgery
Do device characteristics impact outcome in
carotid artery stenting?
Joseph P. Hart, MD,a,c Patrick Peeters, MD,b Jurgen Verbist, MD,b Koen Deloose, MD,a
and Marc Bosiers, MD,a Dendermonde and Bonheiden, Belgium; and Rochester, NY
Objectives: The study was conducted to identify patient and procedural parameters that negatively impact the 30-day rates
for stroke, death and transient ischemic attack (TIA) after carotid artery stenting (CAS) and that might be modified or
further studied in future efforts to improve CAS.
Methods: This was a retrospective investigation of a dual-center CAS database of 701 consecutive CAS patients (414 men;
mean age, 72.4  8.4). A subset of patient-related, lesion-related, or procedure-related variables (age >80, left sided
lesion, symptomatic, nicotine abuse, hypertension, diabetes mellitus, other peripheral vascular disease, hypercholester-
olemia, embolic protection devices usage, predilation, ulcerated lesion, echolucent plaque, restenosis after surgery) were
analyzed for association with occurrence of stroke, death, or TIA <30 days after CAS. The odds ratio (OR) and 95%
confidence interval (CI) and P value were calculated for each variable to predict adverse outcome.
Results: The overall combined rate of stroke, death, and TIA within this database was 3.7% at 30 days. In the total
population of 701 patients, only the OR of 2.7 for hypercholesterolemia (95% CI, 1.0 to 7.3; P  .041) was found to be
significant. Subgroup analysis of the 304 symptomatic patients (43%) showed that open-cell stent designs and concentric
EPD designs yielded an OR of 4.1 (95% CI, 1.4 to 12, P .0136) and 3.3 (95% CI, 1.016 to 10, P .0525), respectively,
for 30-day stroke/death/TIA within this database. Analysis of open-cell stent designs and concentric EPD designs in
patients with echolucent lesions yielded an OR of 3.1 (95% CI,1.2 to 8.2, P  .0343) and 3.7 (95% CI, 1.3 to 10, P 
.0174), respectively, for 30-day stroke/death/TIA.
Conclusions:We conclude that increased analysis of device design variables may be necessary. Particularly in symptomatic
patients or with echolucent lesions, closed-cell design and eccentric filters seem superior. Prospective investigation
comparing open-cell vs closed-cell stents and eccentric vs concentric filter devices may be warranted. (J Vasc Surg 2006;
44:725-30.)Carotid artery stenting (CAS) continues to evolve as an
alternative to carotid endarterectomy.1-5 Although CAS is
generally associated with low intraprocedural and postpro-
cedural adverse neurologic events, it is mandatory to con-
tinuously undertake efforts to further reduce the rate of
adverse events because these have a major effect on patient
outcome.6-16 As advances in access techniques, closure
devices, patient monitoring and selection, preprocedural
imaging, pharmacotherapy, and CAS-specific devices (stents
and embolic protection systems) evolve, it is reasonable to
hope that complication rates—neurologic and otherwise—
will further decrease.
Differently designed carotid stents and embolic protec-
tion devices (EPDs) are available, and theoretic differences
in, specifically, closed-cell vs open-cell stent designs as well
as in eccentric vs concentric EPD designs may exist.17-19
Unique issues exist in stenting within cervicocerebral vas-
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doi:10.1016/j.jvs.2006.06.029cular beds that may lead to different mandates for stent
design compared with other peripheral uses. Closed-cell
stent designs cover a greater percentage of the vascular wall
within a stented region and may better contain fractured
plaque and debris during CAS than open-cell designs.
Similarly, differences in eccentric vs concentric EPDs in-
clude the possibility of different filter behavior when de-
ployed in a tortuous distal internal carotid artery, poten-
tially leading to malposition and ultimately to differences in
the degree of neurologic protection.
We reviewed a centralized dual center database of 701
successful CAS procedures to identify such risk factors. It is
hoped that through such analysis (1) that patient factors or
device characteristics, or both, might be found that would
identify patients at higher risk during CAS, and (2) areas for
potential future study of patient factors or device character-
istics may be identified. Accordingly, we undertook an
analysis of patient risk factors and device characteristics in
light of adverse 30-day outcome after CAS to seek factors
that might be modified or further studied in future efforts
to improve CAS.
METHODS
Patients. During a 67-month period, from January
2001 until August 2005, 709 patients were scheduled to
undergo percutaneous carotid revascularization in the De-
partment of Vascular Surgery of the AZ St-Blasius in
Dendermonde, Belgium and theDepartment of Cardiovas-
cular and Thoracic Surgery of the Imelda Hospital in
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(1.1%) of 709 patients because of unsuccessful EPD deliv-
ery or deployment, and all were converted to carotid end-
arterectomy. As outlined in Table I, the patient-related,
lesion-related, and procedure-related data of the 701 pa-
tients receiving CAS (414 men; mean age, 72.4  8.4)
were collected and entered into the joined investigational
database of the two hospitals for analysis. The assessed
variables and their frequency were analyzed for association
30 days after CASwith occurrence of stroke, defined as all
strokes with symptoms persisting 24 hours; death (all
deaths); or transient ischemic attack (TIA), defined as
neurologic deficits lasting less than 24 hours.
Routine investigations. All patients underwent pre-
operative duplex ultrasound scanning and magnetic reso-
nance angiography along with a complete evaluation by a
neurologist. These tests were used to determine the degree
of stenosis, rule out coexistent proximal or distal disease,
and assess the lesion for echolucency, thrombus, and ulcer-
ation. All findings were subsequently confirmed by digital
subtraction angiography at the time of CAS. Every patient
underwent neurologic evaluation at predetermined time
points: preprocedure, 24 hours postprocedure, and at a
30-day follow-up visit.
CAS procedure. CAS was performed according to
this unit’s existing standards of care as described previ-
ously.20,21 Protected CAS was performed in 671 patients
(95.7%). Distal filtration systems were used in 639 patients
(91.2%), proximal occlusion in 31 (4.4%), and distal occlu-
sion in one (0.1%). Eccentric filters (ie, filter eccentrically
located of working wire) were selected in 520 patients
(74.2%), and concentric filters (ie, filter concentrically po-
Table I. Risk factor analysis adverse events within 30 days
Total population (n  70
Variable Frequency, n (%) OR (95% CI)
Age 80 114 (16) 2.4 (1.0-5.6)
Left side lesion 328 (47) 1.3 (0.6-2.9)
Symptomatic 301 (43) 1.6 (0.7-3.6)
Nicotine abuse 179 (26) 1.3 (0.6-3.1)
Hypertension 524 (75) 0.9 (0.4-2.1)
Diabetes mellitus 158 (23) 1.3 (0.5-3.1)
Other PVD 225 (32) 1.3 (0.5-2.9)
Hypercholesterolemia 436 (62) 2.7 (1.0-7.3)
EPD utilized 671 (96) 1.7 (0.4-7.4)
Lesion predilated 46 (6) 1.3 (0.3-5.7)
Ulcerated Lesion 136 (19) 1.3 (0.5-3.3)
Echolucent lesion 480 (68) 1.0 (0.4-2.4)
Restenosis after surgery 22 (3) 2.4 (0.5-11)
Open-cell stent used 145 (21) 2.2 (1.0-5.1)
Concentric EPD used 119 (17) 2.3 (0.9-5.4)
Open-cell stent used 
echolucent lesion 110 (16) 3.1 (1.2-8.2)
Concentric EPD used 
echolucent lesion 87 (12) 3.7 (1.3-10)
OR, Odds ratio; CI, confidence interval; PVD, peripheral vascular disease; E
*P  0.05.sitioned on working wire) were administered in 119(17.0%). Table II gives a detailed overview of the selected
filter devices.
Carotid stents were used in 695 interventions (99.1%).
Closed-cell stents (ie, all stent-struts are interconnected)
were used in 549 patients (78.3%) and open-cell stent (ie,
not all stent-struts are interconnected) implantation was
performed in 145 (20.7%). Table III gives a detailed over-
view of the selected stents.
Statistical analysis. The odds ratios (OR) and 95%
confidence intervals (CI) and P value were calculated and
used to analyze the different risk factors and their relation-
ship to adverse events22 using a commercially available
software package (InStat, GraphPad Software Inc, San Di-
ego, Cali). ORs are a statistical tool somewhat similar to
relative risk and are essentially the ratio of the probability
that the event of interest occurs to the probability that it
does not occur. ORs are especially useful for interpretation
of case–control studies as this. The OR can take values
he total and symptomatic populations
Symptomatic population (n  301)
P Frequency, n (%) OR (95% CI) P
NS 49 (16) 2.2 (0.6-7.2) NS
NS 125 (42) 1.4 (0.4-4.2) NS
NS — — —
NS 79 (26) 1.5 (0.5-4.9) NS
NS 212 (70) 1.5 (0.3-7.1) NS
NS 68 (23) 1.3 (0.4-4.5) NS
NS 64 (21) 2.1 (0.7-6.7) NS
.0410* 178 (59) 6.6 (0.6-51) NS
NS 276 (92) 2.8 (0.2-49) NS
NS 11 (4) 0.8 (0.04-14) NS
NS 65 (22) 0.9 (0.3-3.5) NS
NS 191 (63) 1.5 (0.4-4.8) NS
NS 5 (2) 5.3 (0.5-51) NS
NS 63 (21) 4.1 (1.4-12) 0.0136*
NS 48 (16) 3.3 (1.016-10) 0.0525
.0343* (N/A)
.0174*
mbolic protection device; NS, not significant; N/A, not analyzed.
Table II. Overview and frequency of used distal filtration
embolic protection device
Type/Name N (%)
Eccentric
FilterWire EX/EZ (Boston Scientific Corp,
Natick, Mass) 440 (62.8)
Spider/SpideRX (ev3, Plymouth, Minn) 80 (11.4)
Concentric
Angioguard XP/RX (Cordis, Miami Lakes, Fla) 74 (10.6)
Emboshield (Abbott Vascular Devices,
Redwood City, Calif) 27 (3.9)
Trap (ev3, Plymouth, Minn) 18 (2.6)for t
1)
0
0
0
PD, ebetween zero and infinity. One is the neutral value and
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 4 Hart et al 727means that there is no difference between the groups
compared; closer to zero or infinity means a larger differ-
ence between the groups under comparison. An OR 2.0
with the lower limit of the range of the CI 1.0 was taken
to indicate an association with an increased risk due to a
particular factor or procedural variable. Further, P  0.05
(using Fisher’s exact test to assess the OR calculations) was
determined to indicate a statistically significant observa-
tion.
RESULTS
As outlined in Table IV, the overall combined rate of
stroke, death, or TIA for the total population within this
database was 3.7% (26/701) at 30 days. The breakdown of
events at 30 days was TIA, 2.3% (16/701); stroke, 1.0%
(7/701); and death, 0.4% (3/701). The rates of events in
the symptomatic group were TIA, 3.3% (10/301); stroke,
1.0% (3/301); and death, 0.3% (1/301); and for the
asymptomatic group, TIA, 1.5% (6/400); stroke, 1.0%
(4/400); and death, 0.5% (2/400).
ORs for basic risk factors in the total population (age
80, left sided lesion, symptomatic, nicotine abuse, hyper-
tension, diabetes mellitus, other peripheral vascular disease,
hypercholesterolemia, EPD utilization, predilatation, ul-
cerated lesion, echolucent plaque, restenosis after surgery)
were analyzed and found to be not significant, with the
exception of hypercholesterolemia (OR, 2.7; 95% CI, 1.0
to 7.3, P  .041). All hypercholesterolemia patients in the
Table III. Overview and frequency of carotid stents
Type/name N (%)
Closed cell
Carotid Wallstent (Boston Scientific Corp, Natick,
Mass) 23 (74.6)
X-act (Abbott Vascular Devices, Redwood City,
Calif) 23 (3.3)
NexStent (Endotex, Cupertino, Calif) 3 (0.4)
Open cell
Precise (Cordis, Miami Lakes, Fla) 70 (10.0)
Zilver (William Cook Europe, Bjaeverkov,
Denmark) 37 (5.3)
Protégé (ev3, Plymouth, Minn) 31 (4.4)
Memotherm (Bard, Karlsruhe, Germany) 3 (0.4)
Exponent (Medtronic Vascular, Santa Rosa, Calif) 3 (0.4)
Sinus Superflex (Optimed, Ettlingen, Germany) 1 (0.1)
Table IV. Adverse events at 30 days within the study
groups
30-day outcome
Total %
(n  701)
Symptomatic %
(n  301)
Asymptomatic %
(n  400)
TIA 2.3 (16) 3.3 (10) 1.5 (6)
Stroke 1.0 (7) 1.0 (3) 1.0 (4)
Death 0.4 (3) 0.3 (1) 0.5 (2)
TIA/stroke/death 3.7 (26) 4.6 (14) 3.0 (12)
TIA, Transient ischemic attack.studied population received a dedicated diet program, and72% received statin treatment. The complete breakdown
and analysis of these calculated ORs is summarized in
Table I for both the entire population and the symptomatic
subgroup.
Subgroup analysis of the 301 symptomatic patients
(Table V) showed that in the 298 stented patients, a 30-day
combined stroke/death/TIA rate of 11.1% (7/63) was
found in patients where an open-cell designed stent was
implanted vs 3.0% (7/235) for closed-cell patients, result-
ing in an OR of 4.1 (95% CI, 1.4 to 12, P  .0136) for
open-cell designed stents. In the 280 symptomatic patients
protected with a distal filtration system, 30-day combined
stroke/death/TIA rates of 10.4% (5/48) and 3.4% (8/
232) were recorded for concentric and eccentric filters,
respectively. The OR for concentric filters was 3.3 (95% CI,
1.016 to 10, P  .0525) for the matching rate for stroke/
death/TIA at 30 days.
Subgroup analysis of the 480 patients with echolucent
plaques (Table VI) resulted for the 475 stented patients in
a 30-day combined rate for stroke/death/TIA of 8.1%
(9/110) and 2.2% (8/365) for open-cell vs closed-cell
stents. The corresponding OR was 3.1 (95% CI, 1.2 to 8.2,
P  .0343) for open-cell stent designs. In case a distal
filtration system was selected in the patients with echolu-
cent plaque (n  430), the 30-day combined stroke/
death/TIA rate was 9.2% (8/87) for concentric and 2.0%
(7/343) for eccentric filters. This yielded for the 30-day
stroke/death/TIA rate an OR for concentric filters of 3.7
(95% CI, 1.3 to 10, P  .0174).
DISCUSSION
The impact of various risk factors on the 30-day stroke,
death, and TIA rate was investigated. No differences could
be observed solely considering stroke and death. The sta-
tistical significances were found if TIAs were taken into
account. Thus, any possible observed advantage or disad-
vantage was explained by the occurrence of TIAs in the
periprocedural period. These temporary neurologic events
are likely mediated by small particles that pass through a
stent with insufficient scaffolding or through the interstices
of a stent deployed in an emboligenic CAS lesion. The
observation that most documented events were transient
and resolved rapidly argues in favor of these particles being
within the small end of the range of those that become
clinically symptomatic.
Allowing for this use of TIA in our adverse event rate,
our data indicate that in the 298 symptomatic patients who
received stents, there appeared to be an elevated OR for
adverse events 30 days in those treated with an open-cell
stent (n 63) compared with a closed-cell stent (n 235).
Comparison of free cell area indicates that closed-cell stents
tend to have a lesser free cell area than open-cell stents.
One analysis evaluated the surface area of various stents
used for CAS. The three closed-cell stent designs had cell
surface areas of 1.08 mm2 to 4.7 mm2, and the four
open-cell designs had cell surface areas of 5.89 mm2 to
11.48 mm2 (Houdart, personal communication). A possi-
ble mechanism for closed-cell stent superiority in this series
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area of the Carotid Wallstent (Boston Scientific, Natick,
Mass) was the lowest of the seven analyzed (1.08mm2) and
was the dominant stent used in this study, having been used
in nearly 74% of patients.
Thus, closed-cell stents have an intrinsically greater
potential to scaffold and support fractured plaque and
support thrombogenic material away from the moving
blood pool. These data may indicate that closed-cell stents
should be used in symptomatic patients undergoing CAS.
Alternative explanations for these observed data effect may
exist. For instance, one group has noticed increased platelet
activation after open-cell use vs closed-cell stent use.23-25
More complex hematologic factors may thus contribute to
the superiority of closed-cell stent designs in our database.
Likewise, within the 280 symptomatic patients who
received filter protection, the OR for protection from adverse
events 30 days appeared to be elevated with the use of
concentric (n  48) rather than eccentric filters (n  232).
Other clinical and benchtop data suggest that eccentric filters
perform superiorly to concentric filters in terms of TIA pre-
vention and particle capture as well as other criteria. 26-28
We postulate the better wall apposition in the distal
internal carotid artery (ICA) due to axial flexibility may
account for these observations in the use of eccentric filters.
The wires of a concentric filter device may pull it away from
the wall when used in tortuous anatomy. Filter malposition
within the ICA beyond the carotid bifurcation lesion being
treated during CAS may, of course, lead to incomplete
embolic protection during a given CAS case. It is possible
that when in use, floating eccentric filters are more prone to
relatively complete wall apposition, thus resulting in some-
what improved embolic protection during CAS when com-
Table V. Adverse events at 30 days within the symptomat
30-day outcome
Stent design
Open cell %
(n  63)
TIA 9.5 (6)
Stroke 1.6 (1)
Death 0.0 (0)
TIA/stroke/death 11.1 (7)
TIA, Transient ischemic attack.
Table VI. Adverse events at 30 days within the CAS patie
30-day outcome
Stent design
Open cell %
(n  110)
TIA 7.2 (8)
Stroke 0.9 (1)
Death 0.0 (0)
TIA/stroke/death 8.1 (9)
TIA, Transient ischemic attack.pared with concentric filters used during CAS. We thusbelieve that eccentric EPDs should be used in symptomatic
patients undergoing CAS.
When these ORs were calculated for patients with
echolucent plaque, which seems to increase the risk of
stroke during CAS,28 similar observations of relative bene-
fit of closed-cell stents and eccentric EPD’s were demon-
strated.
Limitations of this study include that it is a retrospec-
tive analysis of a centralized database describing a dual-
center experience. The database from which these data are
extracted is maintained in a registry format and, as such, is
subject to the limitations of self-audit. Because these data
were collected in two centers closely working together and
sharing techniques, it is possible that the protocols may
have influence the results observed and thus the conclu-
sions. Retrospective data analysis implies a nonrandomized
device selection, which might bias the study outcome if a
preselection of devices existed for specific lesion types.
Nevertheless, in both participating centers, carotid pro-
cedures at the time were only performed in the perspective
of clinical trials and carotid training programs sponsored by
different medical device companies. All patients in whom
carotid procedures were performed during these single
sessions/trials were planned to be treated with, and re-
ceived, the sponsor’s device. During these sessions, only in
exceptional cases where the patients presented with ex-
treme anatomy were the stents were selected accordingly;
hence, stents and EPDs were randomly assigned in nearly
all of the CAS procedures.
Closed-cell stents and eccentric filter devices predomi-
nate among the devices used in this series. It is a potential
explanation for our results that a preference by the opera-
tor(s) for these devices may be coincident with increased
S patients
Filter design
d cell
235)
Concentric %
(n  48)
Eccentric %
(n  232)
(4) 8.3 (4) 2.6 (6)
(2) 2.1 (1) 0.4 (1)
(1) 0.0 (0) 0.4 (1)
(7) 10.4 (5) 3.4 (8)
resenting with echolucent lesions
Filter design
d cell
365)
Concentric %
(n  87)
Eccentric %
(n  343)
(3) 6.9 (6) 1.5 (5)
(4) 1.1 (1) 0.3 (1)
(1) 1.1 (1) 0.3 (1)
(8) 9.2 (8) 2.0 (7)ic CA
Close
(n 
1.7
0.9
0.4
3.0nts p
Close
(n 
0.8
1.1
0.3
2.2expertise with these devices. This is, however, a high vol-
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lesser-used devices in this series is large. Finally, there is a
preference within this center for a specific closed-cell stent
(eg, Wallstent) and eccentric filter (eg FilterWire, Boston
Scientific) for CAS when there is adverse anatomy gener-
ally, a bovine left common carotid artery (CCA), a tortuous
ICA or CCA, or simply a tougher case overall. If anything,
closed-cell stents and eccentric filters saw use in the tough-
est of the cases in this registry. It stands to reason that
closed-cell stents and eccentric filters would be predisposed
to perform below other devices if these factors were not
controlled for. We did not endeavor to quantify or adjust
for technical complexity for each CAS case. Despite this,
closed-cell stents and eccentric filters performed better than
alternative devices in this analysis.
Optimally, a prospective study comparing closed-cell
stent design vs open-cell stents and comparing eccentric vs
concentric filters in symptomatic and asymptomatic pa-
tients would be useful to address any concerns generated by
these observational data. In light of the limitations pre-
sented, alternative explanations for these data do exist, and
a prospective trial would be necessary before conclusive
resolution that the device characteristics under consider-
ation here materially impact patient outcome.
CONCLUSIONS
Our data support the preferential use of closed-cell stents
and eccentric EPDs in patients undergoing CAS in whom
echolucency is documented on preprocedure duplex exami-
nation or who are symptomatic. Further analysis of device
design variables may be warranted. Particularly in symptom-
atic patients or those with echolucent lesions, closed-cell de-
sign and eccentric filters seem superior in the short term.
Prospective investigation comparing open-cell vs closed-cell
stents and eccentric vs concentric filter devices might be
valuable in further addressing these questions. Until further
data become available, strong consideration should be given
to use of closed-cell stents and eccentric EPDs in symptomatic
patients or patients with echolucent lesionswhen other factors
do not mandate use of other platforms.27
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Dr Jacob Schneiderman (Tel-Hashomer, Israel). You were
talking about preoperative echo evaluation of the carotid plaque,
suggesting that this plaquemay “cause troubles;” namely, generate
CAS related cerebral emboli. However, it is well known that echo
does not provide enough resolution to indicate the size of the
necrotic core or fibrous cap thickness. Therefore, the question
remains: How dependable is echo in carotid plaque assessment for
the decision making process if you cannot obtain tissue character-
ization?
On the other hand, if you were provided with accurate MRI
data demonstrating a sizable lipid-rich necrotic core within the
ICA plaque, would you consider putting aside the idea of CAS and
refer the patient to surgery?
Dr Joseph P.Hart. So you’re saying if there wasMR data that
documented an unstable core?
Dr Schneiderman. Yes, if confronted by dependable preop-
erative MRI data suggesting an unstable plaque, would you refer
this patient to surgery primarily, and not consider CAS at all?
Dr Hart. If you had data that documented the compelling
situation that you’re describing, it would probably be a good idea
to do surgery on that lesion.
Dr Robert Hobson (Newark, NJ). You present an attractive
hypothesis, which however appears to be based on a small number
of events. I suspect you agree that larger case analyses will be
required to validate these results. Are any data with larger registries
or randomized trials available, some of which used different stent
designs and delivery systems, that would corroborate your own
single center data? If not, your observations are useful, but specu-
lative, and should be so identified in your manuscript.
Dr Hart. Certainly, it would be attractive to study this either
in a prospective fashion or to look at other people’s experience in a
combined fashion. I think criticism has been made that a meta-
analysis would have some of the same limitations of this study, but
it would be reasonable to do.
I am not aware of prospective data or other work on this issue.
But certainly, looking at the different trials with different devices,
there does tend to be a trend in the direction of the same things we
have observed here.
Dr Marc Schermerhorn (Boston, MA). Were you able to do
a multivariate analysis to tell us which is more important, filter or
stents? There may be confounding since there is an association of
specific stents with specific filters in the trials and in the marketing
of these devices. So were you able to break it down to see if one was
more important than the other?
Dr Hart. We have not done a really formal multivariate
analysis in that regard. I think that would be attractive. I don’t
know if the “n” is high enough to do it exactly the way you
describe, but certainly that would also add to the validity of thisDr Karl Illig (Rochester, NY). I have two questions for you.
Unlike a lesion in the leg or the kidney, in the carotid we’re trying
to prevent embolization in the future, not just open up the lumen.
My first question is, given your extensive experience, whether you
have any long-term data on the incidence of embolization, or are
there plans to analyze and present your long-term results?
My second question is a little more speculative or even pro-
vocative. I’d like to point out the logical next step that derives from
your data, and suggest that if closed-cell stents are better than
open-cell stents, what about going all the way to a covered stent?
Ignoring the issue of the external carotid for now, have you
considered that as an extreme step of what you have found?
Dr Hart. Second question first. It certainly intuitively would
make sense to look at covered stents. Off the top ofmy head, I want
to say somebody has looked at that in a small series, but I can’t
quote it to you right now. It would make sense to try it, if nothing
else, in a model.
The first question, I have a backup slide there that has some of
our long-term data on these people. I won’t boot that up again
here because it looks like the next presentation is ready, but we are
looking at them long term. It’s a prospective registry. There are
plans to follow that.
In terms of your point about a difference in the lesion, in the
carotid vs in the leg, I think that is an incredibly good point, and we
have talked about that. But we are not just trying to establish flow
here. Flow is important, but certainly the lesions in the carotid are
different, and we have to also prevent concurrent and future
embolization and that is the thought with the closed-cell stents is
they may particularly, acutely, do a better job of keeping any debris
that’s generated within the plaque behind the stent out of the flow
channel and thus out of the brain.
Dr K. Wayne Johnston (Toronto, Ontario, Canada). Can
you define echolucent for me?
Dr Hart. Echolucent is somewhat subjective. You can have
heterogeneous lesions where there may be calcification, and there
is partial calcification, so that is a little subjective certainly.
Dr Johnston. In your manuscript you should certainly, I
think, comment on how consistent this finding is, because I have a
difficult time applying this definition. And finally, are these results
corrected for (1) the experience of the surgeon and (2) which
surgeon it was? Because there may be a clear selection bias in stents.
Dr Hart. We have not gone back and looked at who the
operator was. It’s one of four—in all cases—who is at least assisting
or doing the procedure. And corrected for learning curve, yes, the
learning curve question was occurring to me during an earlier
presentation today, I think that would be a very interesting ques-
tion.
